{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:04:16Z","timestamp":1747155856518,"version":"3.40.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013941","name":"CIBERDEM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013941","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.atherosclerosis.2014.12.006","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T20:04:45Z","timestamp":1418155485000},"page":"213-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients"],"prefix":"10.1016","volume":"238","author":[{"given":"Lu\u00eds","family":"Masana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cabr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Heras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-9145","authenticated-orcid":false,"given":"N\u00faria","family":"Amig\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-3054","authenticated-orcid":false,"given":"Xavier","family":"Correig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Mart\u00ednez-Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 T.","family":"Real","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan F.","family":"Ascaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Julve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Palomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7138-8207","authenticated-orcid":false,"given":"Manuel","family":"V\u00e1zquez-Carrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefa","family":"Girona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Plana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Blanco-Vaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib1","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)","volume":"28","author":"Ryden","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib2","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncpendmet1066","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"5","author":"Mooradian","year":"2009","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib5","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","year":"2009","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib7","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI26206","article-title":"Shotgun proteomics implicates protease inhibition and complement activation in the anti inflammatory properties of HDL","volume":"117","author":"Vaisar","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/ATVBAHA.109.186031","article-title":"Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function","volume":"29","author":"Davidson","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib13","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1194\/jlr.R036095","article-title":"Unraveling the complexities of the HDL lipidome","volume":"54","author":"Kontush","year":"2013","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib14","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","article-title":"Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities","volume":"33","author":"Camont","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11892-008-0010-5","article-title":"Why is HDL functionally deficient in type 2 diabetes?","volume":"8","author":"Kontush","year":"2008","journal-title":"Curr. Diab Rep."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MOL.0b013e328355ca25","article-title":"HDL functionality","volume":"23","author":"Soran","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/17460441.2014.871257","article-title":"High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?","volume":"9","author":"Escola-Gil","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib18","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2337\/db11-0378","article-title":"Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes","volume":"60","author":"Morgantini","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.numecd.2007.04.002","article-title":"Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients","volume":"18","author":"Girona","year":"2008","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2337\/diacare.18.6.896","article-title":"Tests of glycemia in diabetes","volume":"18","author":"Goldstein","year":"1995","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/ajcn\/64.4.587","article-title":"Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits","volume":"64","author":"Lussier-Cacan","year":"1996","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0076-6879(86)28066-0","article-title":"Sequential flotation ultracentrifugation","volume":"128","author":"Schumaker","year":"1986","journal-title":"Meth. Enzymol."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1194\/jlr.D014134","article-title":"Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study","volume":"52","author":"Aragones","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.clinbiochem.2008.09.120","article-title":"The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment","volume":"42","author":"Marsillach","year":"2009","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib26","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1194\/jlr.D600045-JLR200","article-title":"The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity","volume":"48","author":"Gaidukov","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.RES.0000146031.94850.5f","article-title":"Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential","volume":"95","author":"Ribas","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib28","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00216-011-5705-9","article-title":"Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy","volume":"402","author":"Mallol","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib29","series-title":"The Design and Analysis of Clinical Experiments","article-title":"The crossover study","author":"Fleiss","year":"1986"},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11883-011-0212-1","article-title":"Niacin: the evidence, clinical use, and future directions","volume":"14","author":"Villines","year":"2012","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib31","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.2337\/db13-0800","article-title":"An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes","volume":"62","author":"Noonan","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib32","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/ATVBAHA.108.178228","article-title":"Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate","volume":"29","author":"Taskinen","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.amjcard.2011.03.054","article-title":"Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease","volume":"108","author":"Guey","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib34","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2337\/dc06-1948","article-title":"Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients","volume":"30","author":"Hirayama","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2014.12.006_bib35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/ATVBAHA.109.198226","article-title":"Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome","volume":"30","author":"Julve","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014016128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915014016128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T14:44:37Z","timestamp":1589294677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915014016128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0021915014016128"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.12.006","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}